Cargando…
Systematic review and meta-analysis of propofol versus barbiturates for controlling refractory status epilepticus
BACKGROUND: Several studies have compared the efficacy and safety of propofol and barbiturates in the treatment of refractory status epilepticus (RSE). This study aims to quantitatively assess the advantages and disadvantages of propofol and barbiturates in controlling RSE. METHODS: We searched for...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6451279/ https://www.ncbi.nlm.nih.gov/pubmed/30954065 http://dx.doi.org/10.1186/s12883-019-1281-y |
_version_ | 1783409167012200448 |
---|---|
author | Zhang, Qing Yu, Yun Lu, Yu Yue, Hongli |
author_facet | Zhang, Qing Yu, Yun Lu, Yu Yue, Hongli |
author_sort | Zhang, Qing |
collection | PubMed |
description | BACKGROUND: Several studies have compared the efficacy and safety of propofol and barbiturates in the treatment of refractory status epilepticus (RSE). This study aims to quantitatively assess the advantages and disadvantages of propofol and barbiturates in controlling RSE. METHODS: We searched for studies with relevant data from the PubMed, Embase, Ovid, Cochrane Library, Springer Link, Web of Science, and China National Knowledge Infrastructure databases. By calculating odds ratios and standardized mean differences with 95% confidence intervals, we assessed the disease control rate (DCR), case fatality rate (CFR), average control time (ACT), average tracheal intubation placement time (ATIPT), and incidence of hypotension between propofol and barbiturates in treating RSE. RESULTS: Seven studies with 261 patients were included in this analysis. Meta-analysis revealed that the DCR of propofol was higher than that of barbiturates (p < 0.001) and that the CFR (p = 0.382) between the two treatment did not significantly differ in controlling RSE. Propofol shortened the ACT (p < 0.001) of RSE and reduced the ATIPT (p < 0.001) of patients with RSE more extensively than did barbiturates and did not increase the incidence of hypotension (p = 0.737). CONCLUSIONS: In comparison with barbiturates, propofol can control RSE and shorten ATIPT in a more efficient and timely manner. Moreover, the drug does not increase the incidence of hypotension and CFR. |
format | Online Article Text |
id | pubmed-6451279 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-64512792019-04-17 Systematic review and meta-analysis of propofol versus barbiturates for controlling refractory status epilepticus Zhang, Qing Yu, Yun Lu, Yu Yue, Hongli BMC Neurol Research Article BACKGROUND: Several studies have compared the efficacy and safety of propofol and barbiturates in the treatment of refractory status epilepticus (RSE). This study aims to quantitatively assess the advantages and disadvantages of propofol and barbiturates in controlling RSE. METHODS: We searched for studies with relevant data from the PubMed, Embase, Ovid, Cochrane Library, Springer Link, Web of Science, and China National Knowledge Infrastructure databases. By calculating odds ratios and standardized mean differences with 95% confidence intervals, we assessed the disease control rate (DCR), case fatality rate (CFR), average control time (ACT), average tracheal intubation placement time (ATIPT), and incidence of hypotension between propofol and barbiturates in treating RSE. RESULTS: Seven studies with 261 patients were included in this analysis. Meta-analysis revealed that the DCR of propofol was higher than that of barbiturates (p < 0.001) and that the CFR (p = 0.382) between the two treatment did not significantly differ in controlling RSE. Propofol shortened the ACT (p < 0.001) of RSE and reduced the ATIPT (p < 0.001) of patients with RSE more extensively than did barbiturates and did not increase the incidence of hypotension (p = 0.737). CONCLUSIONS: In comparison with barbiturates, propofol can control RSE and shorten ATIPT in a more efficient and timely manner. Moreover, the drug does not increase the incidence of hypotension and CFR. BioMed Central 2019-04-06 /pmc/articles/PMC6451279/ /pubmed/30954065 http://dx.doi.org/10.1186/s12883-019-1281-y Text en © The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Zhang, Qing Yu, Yun Lu, Yu Yue, Hongli Systematic review and meta-analysis of propofol versus barbiturates for controlling refractory status epilepticus |
title | Systematic review and meta-analysis of propofol versus barbiturates for controlling refractory status epilepticus |
title_full | Systematic review and meta-analysis of propofol versus barbiturates for controlling refractory status epilepticus |
title_fullStr | Systematic review and meta-analysis of propofol versus barbiturates for controlling refractory status epilepticus |
title_full_unstemmed | Systematic review and meta-analysis of propofol versus barbiturates for controlling refractory status epilepticus |
title_short | Systematic review and meta-analysis of propofol versus barbiturates for controlling refractory status epilepticus |
title_sort | systematic review and meta-analysis of propofol versus barbiturates for controlling refractory status epilepticus |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6451279/ https://www.ncbi.nlm.nih.gov/pubmed/30954065 http://dx.doi.org/10.1186/s12883-019-1281-y |
work_keys_str_mv | AT zhangqing systematicreviewandmetaanalysisofpropofolversusbarbituratesforcontrollingrefractorystatusepilepticus AT yuyun systematicreviewandmetaanalysisofpropofolversusbarbituratesforcontrollingrefractorystatusepilepticus AT luyu systematicreviewandmetaanalysisofpropofolversusbarbituratesforcontrollingrefractorystatusepilepticus AT yuehongli systematicreviewandmetaanalysisofpropofolversusbarbituratesforcontrollingrefractorystatusepilepticus |